According to MedPage Today, a recent study from Japan found that monotherapy with the investigational oral JAK inhibitor peficitinib may be safe and effective for moderate-to-severe rheumatoid arthritis (RA) compared to placebo.

A 12-week phase 2b study showed patients treated with peficitinib achieved the 20 percent response or American College of Rheumatology (ACR20) criteria for treatment. Almost 55 percent of patients taking 100 mg of peficitinib and 65.5 percent of those taking 150 mg achieved the ACR20 score. This is compared to 10.7 percent of those taking placebo.

Click here for more